Global Hyperhidrosis Study Achieves 105% of Enrollment Goal
Case Study
Mar 20, 2020
IQVIA™ Biotech’s strategic training approach dramatically reduced screen failure rates
IQVIA Biotech was asked to conduct a Phase III safety and efficacy study of a treatment for hyperhidrosis (excessive sweating) at sites in the U.S. and Germany. The study required a large patient population in order to meet all the inclusion criteria. Our past experience with hyperhidrosis studies led to improved collection techniques and site selection in order to shorten the study start-up time. As a result of IQVIA Biotech's strategic training approach, dramatically reduced screen failure rates were achieved.